DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Topoisomerase inhibitor
Topoisomerase inhibitor
Selective DNA-Pkcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy
Anti-Neoplastic Effects of Topoisomerase Inhibitors in Canine Mammary Carcinoma, Melanoma, and Osteosarcoma Cell Title Lines
CLINICAL and PHARMACOLOGICAL STUDIES on the TOPOISOMERASE I INHIBITOR TOPOTECAN Cover Design: G.L.M
Differential Effects of the Poly (ADP-Ribose)Polymerase (PARP
Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance
As New Horizons in Antifungal Treatment
Potentiation of Topoisomerase Inhibitor-Induced DNA Strand Breakage and Cytotoxicity by Tumor Necrosis Factor: Enhancement of To
Topoisomerase II
DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair
In Vitro Synergistic Effects of Anthracycline Antitumor Agents And
Induction of Genotoxic and Cytotoxic Damage by Aclarubicin, a Dual Topoisomerase Inhibitor N
The Dual Topoisomerase Inhibitor A35 Preferentially and Specially Targets Topoisomerase 2A by Enhancing Pre-Strand and Post-Stra
Relationship Between Topoisomerase II-DNA Cleavable Complexes, Apoptosis and Cytotoxic Activity of Anthracyclines in Human Cervix Carcinoma Cells
Self-Assembled Disulfide Bond Bearing Paclitaxel—Camptothecin Prodrug Nanoparticle for Lung Cancer Therapy
Theranostic Nanoparticles
Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Combination Strategies to Improve Targeted Radionuclide Therapy
Download Report
Top View
PI3K/Mtor and Topoisomerase Inhibitors with Potential Activity Against SARS-Cov-2 Infection
MHY440, a Novel Topoisomerase I Inhibitor, Induces Cell Cycle Arrest and Apoptosis Via a ROS-Dependent DNA Damage Signaling Pathway in AGS Human Gastric Cancer Cells
Inception to Application in Breast Cancer
HU-331, a Novel Cannabinoid-Based Anticancer Topoisomerase II Inhibitor
Development of New Novel Bacterial Topoisomerase Inhibitors As Promising Antibiotics with a 5-Amino-1,3-Dioxane Linker Moiety DI
Beyond DNA Cross-Linking: History and Prospects of DNA-Targeted Cancer Treatment—Fifteenth Bruce F
Lung Systemic Treatment
Proquest Dissertations
In Chromosome Instability and Personalized Cancer Therapy
2019 Antibacterial Agents in Clinical Development
UC Berkeley UC Berkeley Electronic Theses and Dissertations
Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
Analysis of Type of Cell Death Induced by Topoisomerase Inhibitor SN-38 in Human Oral Squamous Cell Carcinoma Cell Lines
Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age
Activin-A Enhances Mtor Signaling to Promote Aberrant Chondrogenesis in Fibrodysplasia Ossificans Progressiva
Cancer Treatments Cell Cycle Cell Cycle Regulation Malignant Cell
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives
Drugs Aimed at Targeting Characteristic Karyotypic Phenotypes of Cancer Cells
Natural Photosensitizers in Antimicrobial Photodynamic Therapy
GCNA Interacts with Spartan and Topoisomerase II to Regulate Genome Stability
Directed Evolution of Multiple Genomic Loci Allows the Prediction of Antibiotic Resistance
Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death Lonnie P
Comparing Mtor Inhibitor Rapamycin with Torin-2 Within The
Long-Lasting Reduction in Clonogenic Potential of Colorectal Cancer Cells
Generic (Brand) Name Mechanism of Action Mechanism of Action
The IRE1 Inhibitor Kira6 Curtails the Inflammatory Trait of Immunogenic
Recent Advances in Improved Anticancer Efficacies Of
In Vivo Mechanisms of Chemotherapy-Induced Acute Follicle Loss in the Human Ovary
Repair of Topoisomerase I-Mediated DNA Damage Yves Pommier
A Novel Inhibitor Targets Both Wnt Signaling and ATM/P53 in Colorectal Cancer Jiongjia Cheng1, Mary Dwyer1, Karl J
Enhancement of Chemotherapy and Radiotherapy of Murine Tumours by AQ4N, a Bioreductively Activated Anti-Tumour Agent
DRUG NAME: Daunorubicin
Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections Valerie W. C. Soo1£, Brian W. Kwan 1£, Héctor Queza
Administration of Mtor Inhibitors
Inhibitors of Topoisomerases As Anticancer Drugs: Problems and Prospects
Primary Resistance to ATP-Competitive Mtor Inhibitors for the Treatment of Solid Tumors
Professor Tom Connors and the Development of Novel Cancer Therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK
The Intracellular Redox Environment Modulates the Cytotoxic Efficacy Of
Mrna Median Score Name Description 1 99.7 Etoposide
Phase I Study of Topoisomerase I Inhibitor Exatecan Mesylate (DX-8951F) Given As Weekly 24-Hour Infusions Three of Every Four Weeks